glioblastoma and brain cancers


Glioblastoma is the most frequent primary brain tumor in adults, representing a highly heterogeneous group of neoplasms that are among the most aggressive and challenging cancers to treat. An improved understanding of the molecular pathways has led to the development of various biomarkers and the evaluation of several agents specifically targeting tumor cells and the tumor microenvironment. However, while occasional targeted therapy responses have been documented in patients, to date no targeted therapy has been formally validated as effective in clinical trials. Treatment developments for the glioblastoma are also tested for all brain cancer types.

Sources: Semantic Scholar

brain cancer



131I-TLX-101 (glioblastoma)

186Re-RNL (glioblastoma)

225Ac-DOTA-SP (glioblastoma)

177Lu-DTPA-Omburtamab (brain cancer, medulloblastoma)

131I-Omburtamab (neuroblastoma)

131I-Naxitamab (neuroblastoma)

67Cu-SARTATE (neuroblastoma, meningioma)



What is Glioblastoma? – Brain Tumour Charity

Compassionate Use Program (CUP)

CUP enables patients with life-threatening diseases, such as advanced cancer, to resort to experimental treatments when standard anti-cancer solutions and access to clinical trials are not an option. Access to CUP programs depends on local regulations and can vary from one treatment to another.

Ask your referring physicians for more information regarding CUP.